Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NY › Elizabethtown › NPI 1891785184
Hospital

Elizabethtown Community Hospital

Elizabethtown Community Hospital was paid $14.78M by Medicaid between Jan 2018 and Dec 2024, across 139 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 26% of everything it billed.

33Billing provider infoELIZABETHTOWN COMMUNITY HOSPITAL
ELIZABETHTOWN, NY 12932
33aNPI1891785184assigned 10/27/2005
33bProvider typeCritical Access Hospital
28Total paid$14.78M
24GClaims187,083
24DCodes billed139
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Critical Access Hospital providers in New York

Rank by total paid#3 of 12
Median peer was paid$5.23M
This provider vs. median2.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20183,994$189K
201911,821$589K
202028,079$1.36M
202136,052$1.99M
202238,346$5.40M
202339,733$3.35M
2024incomplete29,058$1.90M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 26% 31,003 26,446 $3.78M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 18% 12,884 12,008 $2.63M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 7.2% 7,349 6,452 $1.06M
99282 Emergency department visit for the evaluation and management, low to moderate severity 6.4% 4,598 4,380 $940K
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 5.9% 4,814 4,509 $876K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 5.9% 5,688 1,734 $870K
36415 Collection of venous blood by venipuncture 4.6% 9,784 8,709 $681K
96361 Intravenous infusion, hydration; each additional hour 4.1% 1,764 1,592 $611K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 3.5% 3,255 3,019 $520K
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 2.4% 2,270 2,096 $361K
80053 Comprehensive metabolic panel 2.2% 11,537 10,394 $323K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 1.9% 2,515 2,452 $278K
127 more codes
74177 Computed tomography, abdomen and pelvis; with contrast material 1.0% 552 $150K
70450 Computed tomography, head or brain; without contrast material <1% 421 $141K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 1,001 $138K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 672 $120K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,790 $114K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 2,669 $99K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 868 $94K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 833 $91K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 319 $69K
81025 <1% 1,340 $55K
80048 Basic metabolic panel (calcium, ionized) <1% 2,257 $52K
99203 Doctor's office visit, new patient (routine) <1% 177 $50K
80061 Lipid panel <1% 3,633 $48K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) <1% 250 $46K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 1,342 $45K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 140 $44K
97014 <1% 484 $32K
36416 <1% 322 $31K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) <1% 193 $31K
97162 <1% 105 $30K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 12,184 $30K
84443 Thyroid stimulating hormone (TSH) <1% 3,872 $29K
83036 Hemoglobin; glycosylated (A1C) <1% 3,334 $22K
90686 <1% 1,090 $21K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 334 $18K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 69 $13K
99441 <1% 318 $10K
84439 <1% 1,305 $10K
87086 Culture, bacterial; quantitative colony count, urine <1% 2,478 $10K
71046 Radiologic examination, chest; 2 views <1% 1,941 $9K
90460 Immunization administration through 18 years of age via any route, first or only component <1% 662 $9K
90715 <1% 249 $8K
99204 Doctor's office visit, new patient (more involved) <1% 35 $8K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 437 $7K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 333 $7K
99215 Doctor's office visit, returning patient (complex) <1% 45 $7K
86618 <1% 618 $7K
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years <1% 53 $6K
80306 <1% 1,757 $6K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 72 $6K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 65 $5K
99442 <1% 68 $5K
82607 <1% 413 $5K
87070 <1% 864 $4K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 2,057 $4K
92551 <1% 60 $4K
83735 <1% 2,483 $4K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 2,743 $4K
77067 Screening mammography, bilateral, including computer-aided detection <1% 77 $4K
87468 <1% 142 $4K
82728 <1% 377 $4K
81001 <1% 3,074 $3K
93010 Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only <1% 456 $3K
87469 <1% 132 $3K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 1,741 $3K
96127 <1% 158 $3K
87484 <1% 143 $3K
G0444 Annual depression screening, 5 to 15 minutes <1% 72 $3K
96375 Therapeutic injection; each additional sequential IV push <1% 1,550 $3K
86140 <1% 836 $3K
83690 <1% 2,031 $3K
83880 <1% 84 $2K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 98 $2K
73630 <1% 258 $2K
83540 <1% 473 $2K
77063 Screening digital breast tomosynthesis, bilateral <1% 65 $2K
85610 <1% 670 $2K
82746 <1% 129 $2K
87088 <1% 381 $1K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 65 $1K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 146 $1K
84484 <1% 1,758 $1K
83550 <1% 275 $1K
71045 Radiologic examination, chest; single view <1% 663 $1K
86617 <1% 58 $1K
73030 <1% 120 $1K
87186 <1% 428 $1K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 521 $1K
85651 <1% 311 $1K
87184 <1% 388 $1K
86803 <1% 189 $1K
90656 <1% 85 $1K
85027 <1% 465 $978.95
87081 <1% 440 $950.66
90734 <1% 36 $948.96
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 756 $941.50
73610 <1% 279 $896.82
87077 <1% 183 $702.08
83605 <1% 918 $688.63
82043 <1% 169 $658.39
84702 <1% 118 $626.56
82150 <1% 357 $533.97
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 320 $492.02
81003 <1% 976 $488.01
90677 <1% 13 $413.17
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 302 $392.94
73110 <1% 68 $322.98
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 206 $320.93
73564 <1% 85 $317.73
73130 <1% 69 $308.28
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 660 $301.54
82570 <1% 97 $265.81
86141 <1% 250 $263.33
85379 <1% 159 $169.50
87040 <1% 194 $166.40
82248 <1% 30 $80.10
84703 <1% 38 $79.11
90461 <1% 25 $71.60
90472 Immunization administration, each additional vaccine (list separately) <1% 276 $70.41
J7120 Ringers lactate infusion, up to 1000 cc <1% 561 $63.40
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 1,956 $57.44
J7030 Infusion, normal saline solution , 1000 cc <1% 610 $54.88
81002 <1% 51 $47.79
86756 <1% 14 $41.75
85730 <1% 37 $40.46
J2270 Injection, morphine sulfate, up to 10 mg <1% 51 $32.09
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 17 $31.82
86038 <1% 12 $24.84
86753 <1% 15 $24.60
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 97 $24.21
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 912 $23.41
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 24 $22.98
85652 <1% 12 $21.23
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 28 $8.48
82962 <1% 226 $4.60
S0119 Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) <1% 150 $2.15
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 99 $0.40

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOULA, RODNEY (CEO)